Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.85% | 18.58% | 49.22% | -14.20% | 11.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.19% | 116.03% | 123.32% | 26.16% | 21.96% |
| Operating Income | -106.19% | -116.03% | -123.32% | -26.16% | -21.96% |
| Income Before Tax | -0.21% | 12.94% | 29.45% | 50.75% | -98.56% |
| Income Tax Expenses | -46.53% | 80.36% | 180.56% | 94.23% | 94.23% |
| Earnings from Continuing Operations | -0.20% | 12.92% | 29.43% | 50.74% | -98.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.20% | 12.92% | 29.43% | 50.74% | -98.55% |
| EBIT | -106.19% | -116.03% | -123.32% | -26.16% | -21.96% |
| EBITDA | -104.51% | -114.86% | -123.17% | -26.21% | -22.19% |
| EPS Basic | 72.64% | 81.59% | 87.22% | 90.35% | 45.15% |
| Normalized Basic EPS | 15.32% | 54.68% | 68.25% | 82.82% | 80.04% |
| EPS Diluted | 72.67% | 81.61% | 87.21% | 90.35% | 45.12% |
| Normalized Diluted EPS | 15.32% | 54.68% | 68.25% | 82.82% | 80.04% |
| Average Basic Shares Outstanding | 81.82% | 201.16% | 420.68% | 538.35% | 591.68% |
| Average Diluted Shares Outstanding | 81.82% | 201.16% | 420.68% | 538.35% | 591.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |